CoreFirst Bank & Trust Takes Position in Eli Lilly and Company (NYSE:LLY)

CoreFirst Bank & Trust purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 950 shares of the company's stock, valued at approximately $733,000.

A number of other institutional investors also recently added to or reduced their stakes in LLY. Haverford Trust Co grew its position in Eli Lilly and Company by 983.2% during the fourth quarter. Haverford Trust Co now owns 38,075 shares of the company's stock worth $29,394,000 after buying an additional 34,560 shares during the period. Interchange Capital Partners LLC raised its position in Eli Lilly and Company by 11.3% during the fourth quarter. Interchange Capital Partners LLC now owns 1,181 shares of the company's stock worth $912,000 after acquiring an additional 120 shares during the last quarter. ICW Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1,157.6% in the fourth quarter. ICW Investment Advisors LLC now owns 6,615 shares of the company's stock valued at $5,107,000 after purchasing an additional 6,089 shares in the last quarter. Jackson Thornton Wealth Management LLC grew its position in shares of Eli Lilly and Company by 37.6% in the fourth quarter. Jackson Thornton Wealth Management LLC now owns 779 shares of the company's stock valued at $601,000 after purchasing an additional 213 shares during the last quarter. Finally, Woodmont Investment Counsel LLC increased its stake in shares of Eli Lilly and Company by 121.2% during the 4th quarter. Woodmont Investment Counsel LLC now owns 10,687 shares of the company's stock worth $8,251,000 after purchasing an additional 5,856 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Remove Ads

Eli Lilly and Company Price Performance

Shares of LLY traded down $8.27 during trading hours on Thursday, hitting $818.49. 982,349 shares of the company were exchanged, compared to its average volume of 3,665,517. The firm has a fifty day simple moving average of $841.16 and a 200-day simple moving average of $837.54. The company has a market capitalization of $776.07 billion, a PE ratio of 69.95, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Bank of America reaffirmed a "buy" rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,009.72.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.